Stacey Johnson Takes the Helm as COO of Prolerity Clinical Research Network

Prolerity Clinical Research Welcomes Stacey Johnson as COO

Prolerity Clinical Research, a prominent clinical research site network operating 12 locations across Louisiana, Florida, New Jersey, and New York, has made a significant appointment by naming Stacey Johnson as their new Chief Operating Officer (COO). With over two decades of experience in clinical research, Stacey is set to enhance operational strategies and foster growth within the network.

Stacey comes to Prolerity with a wealth of knowledge gained from her tenure in various executive roles including Vice President of Clinical Operations at WCG and COO at Meridien Clinical Research. Her extensive background in site operations and commitment to quality positions her as an exceptional fit for Prolerity’s mission of advancing patient care through effective clinical research.

Jeff Williams, CEO of Prolerity, expressed enthusiasm about Stacey’s joining the team. He stated, “We could not be more fortunate to have Stacey join the Prolerity team. Her leadership and vision closely align with our commitment to quality and excellence, ensuring we continue to meet the needs of our drug development partners.” This sentiment reflects the confident and strategic direction in which Williams hopes to steer the company.

In her new role, Stacey will oversee operations across the network, ensuring that each research site maintains high standards while also supporting strategic initiatives aimed at expanding Prolerity’s presence in the clinical research sector. Her leadership is expected to be pivotal in streamlining processes and enhancing the overall efficiency of the organization.

Stepping into her role, Stacey expressed her excitement about joining Prolerity Clinical Research. “I am thrilled to be part of a team that is dedicated to being a high-value partner for biopharmaceutical companies and CROs seeking sites capable of delivering access to diverse patient populations,” she affirmed. This enthusiasm signals her eagerness to contribute to the success of the organization and its goals to improve patient welfare through clinical trials.

Prolerity Clinical Research stands out in the industry not only for its commitment to quality but also for its specialized therapeutic coverage. The network is involved in complex Phase I–III trials that encompass various fields, including gastroenterology, cardiology, central nervous system disorders, and metabolic diseases.

Among its notable operations are New Orleans-based Tandem Clinical Research and ClinCloud, located in Florida, both of which are recognized for their strengths in conducting cutting-edge research, particularly in studies related to liver diseases and CNS disorders. The expertise of these sites in study feasibility, patient recruitment, and retention underscores Prolerity's commitment to excellence in clinical trials.

Additionally, Prolerity manages all clinical research initiatives within Allied Digestive Health, the largest gastroenterology and hepatology practice in the Northeast United States. With over 80 locations and more than 350 providers across New Jersey and New York, this network specializes in liver disorders, cardiometabolic issues, and various gastrointestinal diagnostic trials, emphasizing the importance of high-quality research.

Stacey Johnson's leadership comes at a critical time for Prolerity as it seeks to further its mission in clinical research. With her appointment, the organization is well-positioned to tackle the complexities of the changing healthcare landscape. Prolerity is committed to improving patients' quality of life while helping its drug development partners achieve their study objectives through a robust and expanding network.

In conclusion, the appointment of Stacey Johnson as COO marks a pivotal moment for Prolerity Clinical Research. Her extensive experience and proven track record in the clinical research domain promise to propel the company toward greater heights in operational excellence and market presence, ultimately benefiting patients and stakeholders alike.